10:46 uur 17-02-2021

BIOCORP ondertekent twee nieuwe partnerschappen met Mallya Technology

  • Integratie met digitale applicaties ontwikkeld door SocialDiabetes en Heath2Sync
  • Opening van nieuwe, veelbelovende internationale markten met meer dan 850.000 gebruikers

ISSOIRE, Frankrijk – (BUSINESS WIRE) – Regelgevend nieuws:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Parijs: ALCOR), een Frans bedrijf gespecialiseerd in het ontwerpen, ontwikkelen en produceren van innovatieve medische hulpmiddelen, kondigt vandaag de ondertekening aan van nieuwe partnerschappen met Health2Sync en SocialDiabetes, bedrijven met hoofdkantoor in Taiwan en Spanje , respectievelijk.

Deze twee partnerschappen omvatten de integratie van Mallya, het verbonden apparaat voor insulinepennen, met de digitale applicaties die zijn ontwikkeld door Health2Sync en SocialDiabetes om de kwaliteit van de zorg voor patiënten met diabetes te verbeteren.

BIOCORP Signs Two New Partnerships With Mallya Technology

  • Integration with digital applications developed by SocialDiabetes and Heath2Sync
  • Opening of new high-potential international markets with more than 850,000 users

ISSOIRE, France–(BUSINESS WIRE)– Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.

These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.

In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows self-monitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile.

Health2Sync’s app, through its analytics engine, provides personalized recommendations and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling way that encourages users to stay adherent to treatment plans. Health2Sync’s Patient Management Platform utilizes decision support modules for healthcare providers to deliver effective interventions that are also scalable, with insulin dosing as an example. The patient management platform is deployed in over 260 of diabetes care institutions in Taiwan, Malaysia and Japan, and the mobile app is used by more than 600,000 patients in Taiwan, Japan, USA, Hong Kong, Malaysia, Singapore and Australia.

Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback. This information can be transmitted in real time to treating physicians via a devoted portal to improve the quality of dialogue with patients, optimize treatment plans and offer personalized recommendations.

Éric Dessertenne, CEO of BIOCORP, explained: “These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market. Its integration with the most widely used applications in local markets is a great advantage for the rapid adoption of Mallya in these countries. Health2Sync and SocialDiabetes will enable us to accelerate our penetration in Asia and some Latin American countries, geographical areas where the diabetic population and the use of connected medicine are highly developed”.

Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Insulin dosing data captured by Mallya will significantly enhance the experience of patients on insulin “said Ed Deng, Co-Founder and CEO of Health2Sync. “We expect better adherence and improved outcomes that come as a result of making data available to patients and healthcare providers.”

We are thrilled to initiate this agreement with Biocorp. Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers. Patients increasingly demand combined solutions that provide them with high connectivity and data driven personalized support. This alliance with Biocorp is a big step toward the digital health ecosystem the market is waiting for. “said María Jesús Salido, cofounder & CEO of Social Diabetes.


Founded in 2013, Health2Sync provides a comprehensive health-management platform for people with chronic conditions. Its products combine mobile, cloud, and data analytics, enabling patients to obtain personalized care and allows care providers and family to care for patients remotely. With the largest network of clinics and hospitals, it is the leading solution in Asia that brings an effective, yet scalable solution to diabetes management.

For more information, please visit https://www.health2sync.com


SocialDiabetes is set to become one of the best solutions to foster the digital management of diabetes. Leader in Spanish speaking markets, the company, headquartered in Barcelona with offices in the UK, and Ciudad de Mexico was first created to meet the needs of Victor Bautista, a Type 1 diabetes patient and current CTO & co-founder. A company of patients working for patients, SocialDiabetes provides a system that synchronizes with multiple devices, easily connect patients with the healthcare professionals that are treating them and provides relevant information for decision making in one place.

For more information, please visit www.socialdiabetes.com


Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP’s product portfolio of innovative connected solutions. The company has 70 employees.

BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com.


Jacques Gardette

Chairman of the Board


Éric Dessertenne

Chief Executive Officer

Sylvaine Dessard

Marketing & Communication Director

+ 33 (0)6 88 69 72 85

Bruno Arabian

+33 (0)6 87 88 46 26

Nicolas Daniels

+33 (0)6 63 66 59 22

Check out our twitter: @NewsNovumpr